Introduction

Drusen remains one of the main biomarkers of age-related macular degeneration (AMD). They play a prognostic role and reflect the stage of the disease. Distinguishing drusen parameters provides a personalized risk profile for the transition to geographic atrophy or neovascular AMD. Everyone working with AMD patients should know how to detect, quantify, and track drusen on OCT.

What are the types of drusen?

Drusen are accumulations of pathological material of lipid-protein nature, localized under the PES. They reflect impaired transport and exchange between the retinal pigment epithelium and Bruch’s membrane. Historically, they are divided into hard, soft, reticular pseudodruses (or subretinal drusenoid deposits) and other less common types (confluent, pachidruses) as well as other retinal OCT biomarkers for drusen segmentation.

Hard drusen

On ophthalmoscopy, they are small, rounded, clearly delineated foci of yellowish-white color. On OCT, they look like local deposits of hyperreflective material under the PES with a diameter of no more than 63 microns. In small quantities (up to 8), they are not a sign of pathology. They are asymptomatic in most patients.

Soft drusen

Soft drusen are larger than hard drusen and appear as extensive foci with blurred edges on the fundus. On OCT, they are dome-shaped and elevated above the PES and are divided into medium (63-125 μm) and large (more than 125 μm) in size. They are more strongly associated with AMD progression, especially when accompanied by pigmentary abnormalities and other OCT biomarkers (hyperreflective foci, destruction of the ellipsoidal zone, etc.). Soft drusen can enlarge and merge. An area of ​​merging drusen with a diameter exceeding 350 μm is called a drusenoid detachment of the PES.

Soft drusen detected by Altris IMS. AI models are for Research Use Only. Not for use in diagnostic purposes. 

Confluent drusen

These are multiple small deposits under the PES, which can occur in relatively young patients; on FAG they often show a “starry sky” appearance. On OCT, there are multiple small symmetrical elevations of the PES, small in diameter (like hard drusen), but more numerous, prone to merging. The course is variable: some patients maintain a stable course for years, some have an increased risk of complications and transition to the late stages of AMD.

Reticular pseudodrusen (or subretinal drusenoid deposits)

They differ fundamentally in their localization, being located above the PES (in the subretinal space). They contain some common proteins with soft drusen, but differ in lipid composition. Due to their close location to the important photoreceptor layer, they are more often combined with a decrease in visual function, and also carry a higher risk of progression to late AMD (especially characterized by a rapid transition to geographic atrophy (GA) and the development of macular neovascularization (MNV) type 3).

What are the levels of drusen?

The AREDS size classification is still useful in clinical practice: small <63 μm, medium 63–124 μm, large ≥125 μm. Analyses confirm that the 5-year risk of progression to late AMD increases with the number and size of drusen in both eyes and especially with the presence of reticular pseudodrusen. In the NICE guidance for the management of patients with AMD (2018), the risk of progression also depends on the size and type of drusen, as well as the presence of associated pathological changes (pigmentary abnormalities, vitelliform deposits).

The OCT era has added powerful quantitative metrics with AI for drusen measurement and monitoring:

• drusen height (μm),
• area (mm²),
• volume (mm³),
• topography (central ring within 1.5 mm; parafovea 3–5 mm),
• dynamics of changes and associated biomarkers (hyperreflective foci, ellipsoidal zone disruption, presence of hypertransmission zones, etc.).

A practically significant increase in the volume of drusen in the macular region over a year/two correlates with structural and functional deterioration (destructive changes in the photoreceptor layer, changes in ONL thickness, visual acuity). Data from multicenter projects (such as MACUSTAR) confirm the repeatability of measurements and the possibility of comparison between devices, provided that the correct algorithms are used.

What do drusen look like on OCT?

On B-scan OCT, classic hard and soft drusen are localized deposits of hyperreflective material between the PES and Bruch’s membrane (under the PES). Reflectivity can be uniform or heterogeneous depending on the structure and stage of development. Reticular pseudodruses are localized between the photoreceptor layer and the PES (above the PES) – this is the key difference from conventional drusen. On OCT images, they appear as tubercles in the subretinal space that remodel the outer layers of the retina (in particular, the ellipsoidal zone), and on en face, they are visualized as punctate structures, usually connected in a mesh pattern.

A: Soft drusen. B: Hard drusen (Source) Another classic white and black scan

In addition to the drusen themselves, clinically significant are hyperreflective foci, destruction of the ellipsoidal zone, thinning of the outer layers/ONL, formation of hyperreflective foci in OCT or geographic atrophy with the effect of hypertransmission – it is the combinations of these features that form prognostic models of the transition of intermediate AMD to late stages. The combination of these biomarkers consistently exceeds single morphometric thresholds.

En Face Optical Coherence Tomography Illustration of the Trizonal Distribution of Drusen and Subretinal Drusenoid Deposits in the Macula (Source)

As we can see, en face and linear OCT scans help to differentiate different types of drusen and track their progression dynamics. Modern deep learning models for AI drusen examination and en face analysis, like Altris.AI, reliably detect and segment classic drusen from subretinal drusenoid deposits, improving repeatability and reporting speed. You may see the difference from the classic white and black image analysis here:

Confluent drusen are highlighted by Altris IMS. AI models are used for Research Use Only. Not for use in Diagnostic Purposes. 

How to measure drusen size?

Here we can find how drusen are measured:

1) Classical size scale (AREDS):

Orientation on diameter or equivalent on planar reconstructions: <63, 63–124, ≥125 μm. Convenient, but does not take volume/height or topography into account.

2) Quantitative OCT analysis of PES elevation:

On ZEISS CIRRUS instruments, the Advanced RPE Analysis module automatically calculates the area and volume of PES elevation in standard 3 and 5 mm rings around the fovea; the minimum height that the system consistently includes in quantitative results is about 19–20 μm. This provides repeatable metrics and a common “language of numbers” for clinical and research purposes.

3) Morphometric rule for differentiation of drusen and drusenoid detachment of PES:

By basal width: <350 μm – drusen, ≥350 μm drusenoid detachment of PES.

4) AI segmentation and 3D morphometry:

Deep networks segment Bruch’s membrane, PES, and ellipsoidal zone, as well as PES elevation on OCT, calculating drusen height/area/volume and generating dynamics maps. Validation work in 2023–2025 will demonstrate robustness between different OCT devices, which is critical for multicenter networks. Besides, you may track drusen progression on OCT AI tool and stay informed ahead of time to prevent more severe pathology changes in advance.

Can drusen exist without macular degeneration?

Yes, and this is possible in the following cases.

Small (<63 μm) single drusen may occur in the elderly in the absence of other signs of AMD and concomitant risk biomarkers (hyperreflective foci, ellipsoidal zone abnormalities). In this phenotype, the 5-year risk of progression is low; routine monitoring at an interval of 1 time per year is sufficient, if possible, with recording quantitative indicators on OCT (volume/area of ​​PES elevation) for comparison in dynamics. The patient should be informed that the fact of “small drusen” alone does not equal a diagnosis of AMD and does not require treatment, but it is advisable to maintain lifestyle modification (blood pressure control, smoking cessation, a healthy diet).

Confluent drusen are sometimes found in younger patients; they do not always fit into the classic models of AMD. Tactics – individual observation with an emphasis on high-quality OCT documentation (the same scan and control of concomitant biomarkers). In the absence of “red flags”, a 6-12 month follow-up interval is sufficient.

Understanding Macular Degeneration (Source)

Hereditary dystrophies (EFEMP1-related; associated phenotypes are Doyne’s cellular degeneration of the retina and Leventis’ malady) form drusen-like deposits without the typical pathogenesis inherent in AMD. They have an autosomal dominant inheritance pattern and are characterized by yellow-white deposits, like drusen, accumulating under the PES, often in the peripapillary zone. The clinical picture may include gradual vision loss, impaired contrast sensitivity, or metamorphopsia. In this case, timely detection of the phenotype (age of onset, family history, symmetry, characteristic fundus appearance) and referral for medical and genetic counseling with a subsequent individual follow-up plan, including monitoring of possible complications (neovascularization, atrophic changes).

Drusen vs. drusenoid detachment of PES

Drusen are local elevations of PES above Bruch’s membrane due to deposits of pathological material under PES. Usually multiple, of different diameters, with a tendency to merge with the formation of larger, topographically continuous areas of PES elevation.

Drusenoid detachment of the pigment epithelium is formed from a larger conglomerate of drusenoid material, which in turn is formed as a result of the fusion of drusen.

Another differentiating drusen and drusenoid deposits subtypes on multimodal imaging samples

On B-scan OCT, it has smooth edges, uneven reflectivity, and often retains communication with neighboring drusen. On en face visualization, a conglomerate of elevation is visible, which corresponds to the zone of changes in the PES-Bruch’s membrane complex. In the absence of fluid inside the lesion, we are talking about drusenoid detachment of PES; if homogeneous hyporeflectivity is visualized under PES, this is serous detachment of PES, and if there are signs of a neovascular membrane according to OCTA or FAG, this is fibrovascular detachment of PES. Therefore, in doubtful cases, it is advisable to add OCTA to exclude hidden MNV.

The main morphometric rule: basal width ≥350 μm (in the horizontal projection of the OCT slice favors drusenoid detachment of PES. In some situations, we also pay attention to the content (serous/optically empty space, signs of vascularization), PES profile, and associated biomarkers, since PES detachment is more often associated with the risk of transition to HA or the formation of neovascularization.

What is the best treatment for drusen?

Drusen are not treated as a separate nosology. They are a structural biomarker of AMD, and also have prognostic value for assessing the further development and rate of progression of the disease.

Optimal tactics for detecting drusen:

Optimal tactics for detecting drusen may include the following

Risk modification: 

• smoking cessation,
•  blood pressure control,
• metabolic profile,
• diet.

Dietary supplements based on AREDS 2: 

• taking antioxidant complexes (lutein, zeaxanthin, vitamins C and E, zinc, copper) reduces the risk of transition to late AMD by approximately 25% within 5 years (according to AREDS 2).

Quantitative monitoring on OCT: 

• record the volume/area/height of drusen and their dynamics, distinguish between drusen types, detect other concomitant signs of AMD progression (hyperreflective foci, destructive changes in the ellipsoidal zone, pigmentary anomalies, vitelliform material deposition, signs of formation of foci of geographic atrophy).
• Individualize observation intervals (depending on the type of drusen, the dynamics of their structural changes and other risk factors).
• Among the new promising methods of treating dry AMD at the drusen stage is multiwavelength photobiomodulation.

Multiwavelength photobiomodulation:

This method is aimed at stopping or regressing the progression of dry AMD by modulating mitochondrial activity and consists of the use of specific light (red and near-infrared spectrum from ~590 to 850 nm), which can reduce oxidative stress in retinal cells, inflammation and apoptosis of PES cells.

The efficacy as a potential treatment approach has remained controversial until recently: studies have shown only temporary improvement in visual function and reduction in drusen volume (not maintained for 6 months).

Updated data from the LIGHTSITE III study were presented at the ARVO 2025 conference. They showed that photobiomodulation can significantly slow the decline in visual acuity and reduce the rate of expansion of HA zones

Recently, the FDA approved photobiomodulation for the treatment of AMD.

For complications:

• Neovascular AMD– anti-VEGF.

• Geographic atrophy – injectable drugs (inhibitors of the C3 and C5 complement system), approved by the FDA

The role of AI drusen quantification OCT

The role of AI: automated drusen-volume measurement in OCT is now a reality. IT allows automated segmentation and counting (3D volume, area, height), identification of reticular pseudodruses and other signs of AMD, and compilation of prognostic profiles.

In practice, applying an OCT drusen-counting algorithm reduces variability in assessments and helps personalize visit frequency. Additionally, home OCT monitoring models with AI analysis are being developed, indicating that broader AI support for AMD is fast approaching.

Conclusion

Drusen on OCT are more than just a sign of AMD. They have become one of the most important biomarkers of age-related macular degeneration and a kind of “compass” in the daily practice of an ophthalmologist. Today we understand that:

Drusen come in different types, and, accordingly, carry different prognostic information: hard, soft, confluent, and reticular pseudodrusen. Each type carries a different risk and requires a different surveillance strategy.

Drusen levels are no longer limited to diameter, height, volume, dynamics, and structural features as well as accompanying OCT biomarkers have also become important. It is the combination of these parameters that allows us to predict the transition to the late stages of AMD.

OCT has changed the game: drusen can now be seen in 3D, segmented automatically, build PES elevation maps, and compare data between visits. Thanks to this, the doctor receives a lot of information about the evolution of the disease.

AI sets a new standard: algorithms can accurately calculate drusen volume, identify their subtypes, generate prognostic profiles, and reduce interobserver variability. This translates data from subjective descriptions into objective, reproducible numbers.

Drusen classification on OCT using AI allows not only ascertaining the presence of drusen, but also differentiating their type, objectively measuring their number and parameters, and tracking their dynamics via AI drusen quantification on OCT. For the doctor, this means identifying risk factors in the early stages of retinal disease, accurately comparing data between visits, and prescribing the correct therapy promptly.

Home monitoring is the future that has already begun: the first FDA-approved solutions with “OCT + AI” are currently used to monitor fluid in neovascular AMD, but they pave the way for daily structural monitoring of drusen as well. This means that in the near future, the patient may be able to monitor their own retina at home, and the doctor may be able to see the dynamics in real time.

In the treatment of drusen wet or dry AMD, the main goal remains not to “remove drusen,” but to minimize risks (smoking, diet, systemic factors), prescribe AREDS2-based complexes, timely detect complications, and apply already available therapies (anti-VEGF in INM, C3 and C5 inhibitors of the complement system in HA). Among the new promising methods for treating dry AMD at the drusen stage is multiwavelength photobiomodulation.

It is important to remember when communicating with the patient: drusen is not a therapeutic target, but a structural “compass”. We do not “treat drusen.” Instead, we systematically reduce risks (smoking, blood pressure, nutrition), use drugs based on the AREDS2 formula, and most importantly, we regularly measure their quantitative parameters in dynamics. When complications appear and the transition to a late stage occurs, we prescribe treatment based on the same objective OCT metrics. Thus, instrumental accuracy and AI analytics turn drusen into a manageable marker that helps to timely detect the risks of AMD progression.

Thus, drusen on OCT have become a bridge between morphology and prognosis. They provide an opportunity to build a long-term strategy for preserving vision. Today, the doctor is required not only to see drusen, but also to quantitatively measure, assess in dynamics, calculate the risk, and explain to the patient his individual risks. It is thanks to these approaches that we are moving towards a new paradigm – personalized ophthalmology, where decisions are made based on objective digital data, enhanced by artificial intelligence.

Sources:

1. 1. https://pubmed.ncbi.nlm.nih.gov/39558093/
   2. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2765650
   3. https://link.springer.com/article/10.1007/s00417-024-06389-x
   4. https://iovs.arvojournals.org/article.aspx?articleid=2804052
   5. https://www.ophthalmologyscience.org/article/S2666-9145(25)00182-4/fulltext
   6. https://www.nature.com/articles/s41433-024-03460-z
   7. https://www.ophthalmologytimes.com/view/arvo-2025-update-on-the-lightsite-iii-study-in-amd

Introduction

Central Retinal Vein Occlusion (CRVO) OCT is one of the most common and clinically significant vascular disorders affecting the eye, often resulting in substantial visual impairment. This condition ranks second among causes of vision loss due to vascular disease, after diabetic retinopathy, placing a considerable burden on both healthcare systems and patients’ quality of life. Epidemiological studies show that the prevalence of RVO increases with age, and in populations with concomitant cardiovascular disease, the risk of developing occlusion rises severalfold.

Despite a long history of study, it is the breakthroughs in instrumental diagnostics over the past decade that have fundamentally changed our approach to recognizing and managing RVO. Previously, assessment of the macula and retinal vasculature relied primarily on ophthalmoscopy. While still an important tool, it has inherent limitations.

Optical coherence tomography (OCT) has revolutionized diagnostic standards. With its high resolution and ability to capture subtle structural changes within the retinal layers, OCT has become indispensable for determining disease severity, monitoring treatment efficacy, and conducting long-term follow-up. It allows for the detection of minimal early signs of edema, subclinical structural damage, and initial manifestations of ischemia—changes that were practically inaccessible for dynamic assessment 10–15 years ago.

This level of precision is particularly critical for patients at increased risk of RVO. The most vulnerable groups include individuals with arterial hypertension, diabetes mellitus, glaucoma, coagulation disorders, as well as older adults, in whom the vascular walls may already have undergone degenerative or sclerotic changes.

Importantly, modern RVO treatments require objective dynamic monitoring. OCT enables precise evaluation of structural changes, tracking of therapeutic response, and individualization of treatment strategies, helping to avoid both overtreatment and undertreatment.

Thus, the role of OCT today goes far beyond simple visualization: it is a key tool for prognostic assessment, patient stratification, optimization of therapeutic decisions, and timely detection of complications.

1. What RVO Is and Why It Occurs?

Central Retinal Vein Occlusion (CRVO) OCT is a disruption of venous blood outflow in the retina due to partial or complete vein occlusion. As a result, the following occur:

• Blood stasis
• Increased venous pressure
• Impaired capillary perfusion
• Retinal edema, especially in the macular area
• Risk of neovascularization

Early detection is critical, as prompt treatment—particularly for macular edema—significantly increases the chances of preserving or restoring vision. Delayed diagnosis can lead to progression of ischemia, neovascularization, neovascular glaucoma, and persistent macular dysfunction.

RVO also has important systemic implications: patients with a history of RVO have a higher risk of acute cardiovascular events (myocardial infarction, stroke, heart failure) compared with the general population. This emphasizes the need for comprehensive management, involving not only ophthalmologists but also other specialists, such as cardiologists.

Central vs. Branch Retinal Vein Occlusion: Pathogenesis Differences

• Central Retinal Vein Occlusion (CRVO) occurs when blockage happens at the level of the lamina cribrosa. Compression, arterial wall thickening, or thrombotic processes disrupt blood outflow from the entire retina. Typical signs include:
  • Diffuse hemorrhages
  • Marked macular edema
  • Increased risk of optic disc and iris neovascularization due to severe ischemia
  • Generally worsen prognosis than branch occlusions
• Branch Retinal Vein Occlusion (BRVO) usually occurs at arteriovenous crossings, where a thickened artery compresses a vein, causing localized occlusion. Characteristic features include:
  • Localized edema and hemorrhages
  • Clear segmental distribution
  • Prognosis is generally better than that of CRVO, though macular edema may persist

Key Risk Factors for RVO
Modern studies and guidelines identify the following as the main risk factors:

• Arterial hypertension
• Atherosclerosis and age-related vascular changes
• Diabetes mellitus (even without diabetic retinopathy)
• Glaucoma and elevated IOP
• Hypercoagulable states, thrombophilia
• Obstructive sleep apnea
• Age >50 years

Rare cases of RVO associated with thromboembolic complications after COVID‑19 infection or vaccination have also been reported, highlighting the ongoing relevance of thrombotic mechanisms.

Impact on Microcirculation and Vision

RVO leads to:

• Impaired normal venous outflow
• Sharp elevation of hydrostatic venous pressure
• Damage to the blood-retinal barrier
• Leakage of plasma and cellular elements into the retinal interstitium, causing macular edema
• Development of ischemic zones
• Over time, thinning of inner retinal layers, neuroepithelial atrophy, and damage to the photoreceptor layer

These changes are best assessed with OCT, which enables precise patient stratification and treatment planning. Timely diagnosis, proper monitoring, and early therapy are essential.

2. OCT Signs of Retinal Vein Occlusion: Detecting Subtle Changes

With the advent of OCT, detection of structural retinal changes in RVO has significantly improved—even at early stages without obvious clinical signs.

Acute Stage Changes (first weeks after occlusion)

• Macular edema:
  • Cystic spaces in inner retinal layers (INL, OPL)
  • Increased central retinal thickness
  • Subretinal fluid (serous neurosensory detachment)
• Intraretinal hemorrhages: appear on OCT as hyperreflective areas with shadowing of underlying layers
• Ischemia indicators:
  • Hyperreflectivity of neuroepithelium
  • Cotton-wool spots

Chronic Stage Changes (months later)

• Chronic ischemic and atrophic changes (thinning of inner retinal layers)
• Disruption of photoreceptor layer (ELM and EZ)
• Disorganization of inner retinal layers (DRIL)
• Persistent edema (>6 months) indicates chronic RVO requiring therapeutic adjustment

AI for OCT thus allows both acute diagnosis and long-term monitoring of ischemic progression or tissue remodeling.

3. Assessment of Macular Changes in RVO Using OCT

Central retinal vein occlusion crvo OCT is now considered the gold standard for diagnosing, monitoring, and assessing treatment response in macular edema, including that associated with RVO.

OCT is highly sensitive for:

• Quantitative and qualitative analysis (central retinal thickness [CRT], macular volume [MV], size and number of cystic spaces, DRIL, photoreceptor layer integrity)
• Evaluating treatment response
• Detecting minimal residual cysts
• Predicting visual acuity outcomes

Typical OCT Findings in RVO:

• Diffuse retinal thickening
• Cystoid macular edema (localized cysts deforming normal retinal architecture)
• Serous neurosensory detachment (indicative of blood-retinal barrier breakdown)
• Disruption of EZ and ELM (photoreceptor involvement, critical for final visual acuity)

These capabilities make OCT an integral part of modern RVO monitoring.

4. Top 3 Challenges in RVO OCT Analysis

Despite its power, OCT assessment of RVO has significant limitations:

1. Need for normative comparison
   Interpretation requires comparison with the patient’s contralateral eye or established normal values. Systemic vascular anomalies can affect both eyes, limiting standardization.
2. Complexity with comorbidities
   Many RVO patients have systemic (hypertension, diabetes) or ophthalmic comorbidities (diabetic retinopathy, AMD, glaucoma, epiretinal membrane), complicating interpretation. It can be difficult to distinguish RVO-related changes from combined pathology.
3. Requirement to consider the clinical context
   OCT provides only part of the clinical picture. Accurate interpretation requires integration of symptoms, medical history, systemic factors, fundoscopic findings, and other diagnostic tests. Anatomical variations, comorbidities (glaucoma, cataract), and individual treatment response also necessitate a personalized approach.

5. Treatment of RVO: Modern Approaches

Currently, no treatment restores normal retinal venous circulation. Therefore, therapy focuses on controlling complications, primarily macular edema and preventing neovascularization (retinal, iris/optic disc, neovascular glaucoma, hemorrhages, and tractional changes).

All RVO patients should receive systemic management, ideally in collaboration between an ophthalmologist and a cardiologist or internist. Monitoring of blood pressure, lipids, glucose, and coagulation factors is essential, as RVO often signals systemic vascular risk.

Treatment decisions must be individualized, considering:

• RVO subtype (CRVO vs. BRVO)
• Edema severity
• Clinical and OCT findings
• Risk of adverse effects
• Patient status (comorbidities, ability for regular follow-up)

Anti-VEGF Therapy as First-Line Treatment

Intravitreal anti-VEGF injections are the first-line therapy for macular edema associated with RVO. These drugs reduce vascular endothelial growth factor (VEGF) expression, lowering vascular permeability, fluid leakage, edema, and inhibiting pathological neovascularization.

Commonly used agents:

• Ranibizumab, Aflibercept, Faricimab: proven safe and effective for CRVO and BRVO-related macular edema brvo vs crvo oct; studies show significant improvements in best-corrected visual acuity (BCVA) and central macular thickness (CMT).
• Bevacizumab: used off-label for macular edema and neovascularization.

Long-term studies indicate anti-VEGF therapy provides sustained visual improvement for many patients, with injection frequency often decreasing over time.

Advantages:

• High efficacy for macular edema
• Good tolerability and safety (systemic complications are rare)
• Personalized treatment possible

Limitations / Challenges:

• Some patients respond insufficiently
• Requires frequent injections (clinic visits, financial burden, potential complications, patient discomfort)
• Chronic or refractory edema may require alternative or combination approaches

Steroid Implants and Injections: Second-Line Therapy

Dexamethasone intravitreal implant (OZURDEX) is approved for RVO-related macular edema, particularly when:

• Anti-VEGF therapy is insufficient
• Frequent injections are impractical (distance, transportation, cost)

Steroids reduce inflammation, vascular permeability, and fluid accumulation, useful in chronic or resistant edema.

Risks / Limitations:

• Cataract (especially with repeated or long-term use)
• Increased intraocular pressure (IOP), potential steroid-induced glaucoma

Laser Therapy

• Panretinal photocoagulation is effective for neovascularization.
• Its use has declined with anti-VEGF availability, which offers strong anatomical and functional results.

Surgical Approaches

• Vitrectomy may be considered in selected cases.
• Surgery carries risks and is reserved for situations where other treatments fail or are inappropriate.

Combination Strategies

• In practice, clinicians often combine anti-VEGF therapy with steroid implants or laser treatment, depending on disease course.
• This can reduce total injection burden, minimize side effects, and improve outcomes in chronic or recurrent edema.

Monitoring Frequency

• Active macular edema or ongoing treatment requires regular OCT follow-up to evaluate therapeutic response and adjust injection intervals.
• OCT schedule:
  • Monthly at treatment initiation
  • Individualized intervals using Treat-and-Extend protocols
  • Structural monitoring to prevent atrophic changes
• Ischemic RVO patients have the highest neovascularization risk within the first 90 days; monthly monitoring during the first 6 months is critical.

Conclusions and Recommendations

RVO is a complex, multifactorial vascular disorder that can cause sudden and severe vision loss, particularly in patients with systemic risk factors. Modern management aims not only to address acute complications but also to control long-term structural retinal changes.

OCT has transformed RVO care by providing:

• Early detection of edema, subclinical ischemia, and architectural changes
• Dynamic monitoring of treatment response, allowing timely adjustments and optimization
• Improved long-term prognostication through evaluation of macular thickness, outer retinal layers, and fluid volume

OCT helps identify edema type and secondary changes—atrophy, photoreceptor damage, inner retinal thinning—allowing a more accurate visual prognosis, especially in ischemic RVO.

When combined with modern anti-VEGF agents, long-acting steroid implants, and personalized dosing regimens, OCT enables:

• Reduction of unnecessary injections via interval optimization
• Maximized treatment efficacy based on morphological findings
• Prevention of recurrence and progression through early detection of edema

Thus, OCT is not merely a visualization tool but a core element of clinical decision-making, improving patient management, preventing complications, and enabling more complete and stable visual recovery.

Clinical Recommendation: Integrate regular OCT assessments into RVO management, with attention to macular thickness dynamics and outer retinal layer integrity for precise disease control and optimized therapeutic outcomes.

References:

1. https://pubmed.ncbi.nlm.nih.gov/38714470/
2. https://www.rcophth.ac.uk/wp-content/uploads/2015/07/Retinal-Vein-Occlusion-Guidelines-Executive-Summary-2022.pdf
3. https://www.mdpi.com/2077-0383/14/4/1183
4. https://www.auctoresonline.org/article/clinical-therapeutic-orientation-in-retinal-venous-obstruction
5. https://www.mdpi.com/2077-0383/10/3/405
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC10801953
7. https://www.mdpi.com/2075-4418/13/19/3100
8. https://karger.com/oph/article-abstract/242/1/8/255831/Microvascular-Retinal-and-Choroidal-Changes-in?redirectedFrom=fulltext
9. https://link.springer.com/article/10.1007/s40123-024-01077-9
10. https://pubmed.ncbi.nlm.nih.gov/39717563/
11. https://provider-rvo.vision-relief.com/introduction/management/

Introduction

The year 2026 in ophthalmology will not be defined by a single “major breakthrough,” but rather by key trends in Ophthalmology and optometry in 2026, and the maturation of several directions whose discoveries and innovations are now transitioning into everyday clinical practice. While just a few years ago innovations were often perceived as isolated technologies far removed from real-world care (a new drug, device, or piece of equipment), today entire ecosystems are being formed: from early detection to long-term monitoring, from the ophthalmologist’s office to optometric screening, from a single consultation to a longitudinal patient journey supported by digital tools.

The core logic of 2026 is a shift from reactive to proactive ophthalmology. Increasingly, the goal is to prevent disease at the stage of risk-factor modification, intervene in the earliest pathological changes, and track preclinical markers. This shift is visible across several dimensions: the growing role of telemedicine and portable diagnostics; autonomous AI becoming a public health tool; and oculomics, which enables ocular image analysis to serve as a source of early biomarkers for systemic conditions. At the same time, the treatment paradigm is evolving: where repeated procedures once dominated (for example, frequent intravitreal injections), 2026 brings a move toward extended-duration regimens, implant-based drug delivery platforms, and disease control with fewer clinic visits.

Another important axis is the alignment of patient expectations. Some new approaches (for example, in the management of dry AMD and geographic atrophy) do not promise to “restore vision,” but rather to buy time—slowing structural retinal damage and functional vision loss. As a result, in 2026, risk–benefit communication and shared decision-making become almost as important as the choice of molecule or device itself.

Below, we outline the key eye care trends of 2026: what is changing, why it matters, and how it will shape ophthalmic and optometric practice.

1. New Approaches to Treatment

1.1. Geographic Atrophy (GA): The Introduction of Active Treatment in eye care trends 2026

1.1.1. Injectable Therapies as Ophthalmology Trends 2026

Following the key trends in Ophthalmology and Optometry in 2026 , development of injectable therapies for geographic atrophy, clinical practice is entering a “second wave” phase—where the main questions are no longer whether therapy is possible for a disease historically considered untreatable, but how that therapy should be practically implemented. In 2026, the focus will be on patient selection, treatment initiation, dosing frequency and duration, as well as monitoring.

Currently, the FDA has approved the following injectable therapies for GA:

• Izervay (avacincaptad pegol) — a C5 complement inhibitor.
• Syfovre (pegcetacoplan) — a C3 complement inhibitor.

Their mechanism of action involves reducing chronic inflammation and cellular damage in the retina and—most importantly—slowing the rate of GA lesion expansion.

Because most available data focus on slowing atrophy progression (an anatomical endpoint) rather than guaranteed improvements in visual acuity, properly managing patient expectations becomes particularly critical in 2026. Clear discussions about therapeutic goals and limitations are emphasized in review publications addressing the first approved GA treatments.

1.1.2. Multiwavelength Photobiomodulation

Multiwavelength photobiomodulation is one of the most promising emerging approaches and key trends in Ophthalmology and Optometry in 2026 aimed at halting or slowing the progression of dry AMD through modulation of mitochondrial activity. The use of specific wavelengths (red and near-infrared light, approximately 590–850 nm) may reduce oxidative stress in retinal cells, inflammation, and apoptosis of retinal pigment epithelium cells.

Its appeal is clear: a non-invasive procedure with significantly better acceptability for some patients compared with regular injections.

Until recently, its effectiveness remained debated, with studies showing only temporary functional improvement and reduction in drusen volume. At ARVO 2025, updated results from the LIGHTSITE III study demonstrated that photobiomodulation can significantly slow visual acuity decline and reduce the rate of GA expansion.

In 2025, the FDA approved photobiomodulation for AMD, creating strong prospects for broader clinical adoption in 2026.

The 2026 trend is correct positioning and stratification:

• Use of photobiomodulation based on clear indications for specific dry AMD stages and patient profiles.
• Transparent communication of expectations, with goals focused on functional support and slowing GA progression rather than guaranteed vision restoration.

1.2. Extended Anti-VEGF Treatment Regimens

Another major trend is the shift toward regimens with reduced injection frequency. This is not merely about comfort, but primarily about preventing missed visits: patients with AMD and diabetic retinopathy with DME often fall out of treatment due to visit burden. Thus, 2026 reinforces the principle that treatment must be effective in real-world conditions, not only under ideal adherence.

The ranibizumab port delivery system (Susvimo, Port Delivery System) has become emblematic of this trend. In 2025, the FDA also approved Susvimo for the treatment of diabetic retinopathy.

1.3. Gene Therapy for Macular Telangiectasia Type 2 (MacTel 2)

MacTel 2 is a chronic, progressive neurodegenerative retinal disease that previously lacked active treatment.

In 2025, the first implantation of ENCELTO (revakinagene taroretcel)—the first and currently only FDA-approved gene therapy for MacTel 2—was performed in the United States. ENCELTO enables a shift from observation to active intervention, with the potential to preserve visual function in early-stage patients.

The device is based on encapsulated cell therapy technology: a capsule containing genetically modified cells that continuously secrete recombinant human ciliary neurotrophic factor (CNTF), acting as a neuroprotective agent that slows photoreceptor degeneration.

In 2026, the focus will move from “innovation storytelling” to routine clinical implementation, including defining early selection criteria, monitoring protocols (OCT biomarkers, functional testing), and accumulating real-world long-term data on photoreceptor preservation and visual function.

1.4. Gene Therapy for Neovascular AMD: Closest to Real Transformation

For neovascular AMD, gene therapy remains one of the most anticipated eye care trends 2026 directions, as it has the potential to fundamentally change treatment logic—from repeated injections to a single vector administration enabling long-term therapeutic protein expression. Reviews published in 2025 highlight active programs such as RGX-314, ADVM-022 (Ixo-vec), 4D-150, and others.

In 2026, the key questions shift from “does it work?” to “how does it work across different patient groups?” including:

• Stability and duration of expression;
• Inflammatory and immune response profiles;
• Need for supplemental anti-VEGF therapy;
• Patient selection criteria;

Injection centers and post-procedure monitoring standards.

2. Oculomics: The Eye as a “Window to the Body” and a Source of Digital Biomarkers

Oculomics is one of the most compelling trends of 2026, as it reshapes ophthalmology’s role within medicine as a whole. The concept is simple: the eye is the only structure where microvasculature, neurons, and signs of metabolic and inflammatory processes can be visualized non-invasively at high resolution. As a result, fundus and OCT/OCTA data may serve as biomarkers for systemic conditions—from cardiovascular risk to neurodegenerative diseases.

In contemporary research, oculomics is described as an approach that uses retinal images to assess systemic risks and conditions, with potential scalability for screening. In 2026, this “scale” becomes critical: data may originate not only from ophthalmology clinics, but also from optometric practices, mobile screening programs, and telemedicine.

What truly changes in 2026:

• A transition from “interesting correlations” to clinical utility, with models expected to demonstrate actionable impact on patient management.
• Data verification and management of false-positive risk, including the communication of systemic risk to patients.
• Integration with AI, as multidimensional patterns often exceed human interpretive capacity.

A major risk in 2026 is over-marketing, reinforcing the need for externally validated models with clear clinical context that do not generate unnecessary “medical noise.”

3. AI Technologies: From Decision Support to Autonomous Screening and Managed Patient Pathways

3.1. Autonomous Diabetic Retinopathy Screening as a Scalable Standard

In 2026, diabetic retinopathy remains the most studied use case for autonomous AI. In the United States, three FDA-approved autonomous DR screening systems are already described (LumineticsCore/IDx-DR, EyeArt, AEYE-DS). This positions AI as a practical tool capable of influencing large-scale screening programs, particularly in primary care, endocrinology clinics, and mobile settings.

The FDA approval of AEYE-DS as a fully autonomous solution (portable camera plus algorithm) underscores that in 2026, AI increasingly “works where the patient is,” not only where an ophthalmologist is present.

3.2. 2026 as the Year of Integration

Successful projects in 2026 will be distinguished by:

• Image quality standards and quality control;
• Clear referral rules and urgency levels;
• Mechanisms to ensure patient follow-through (scheduling, reminders, visit tracking);
• Transparent documentation for clinicians, patients, and audit purposes.

3.3. AI as “Invisible Infrastructure”

In 2026, AI increasingly functions as invisible infrastructure: highlighting high-risk cases, prioritizing queues, generating structured reports, and standardizing interpretation. The impact is reduced variability, faster routing, and fewer missed cases.

4. Telemedicine: From Video Calls to Retinal Screening and Remote Management

By 2026, telemedicine in ophthalmology is no longer synonymous with video consultations. Its foundation is tele-imaging: transmission and assessment of retinal images (fundus photos, sometimes OCT) with structured referral protocols.

At the same time, limitations become more openly discussed. Certain conditions and components of assessment may be less accurately captured remotely, requiring clear protocols to define which patients can be managed remotely and which require in-person examination.

The 2026 trend is a shift from “tool” to “pathway”:

• Tele-screening as the first step;
• Automated or semi-automated reporting;
• Referral and follow-up control;

Remote reassessment for ongoing risk monitoring.

5. New Devices and Portable Diagnostics: Closer, Faster, More Scalable Care

5.1. Portable Diagnostics as the Foundation of Coverage

Portable fundus cameras and compact diagnostic systems represent one of the most practical changes of 2026. Their value lies not only in technology, but in enabling large-scale screening in locations without full ophthalmic infrastructure.

Synergy with autonomous AI (such as AEYE-DS) is especially strong here, supporting new partnership models:

• Endocrinology and primary care clinics;
• Optical stores and optometric practices;
• Mobile programs for workplaces or regions.

5.2. Devices Deliver Value Only with Quality Protocols

Success depends not just on acquiring devices, but on defined protocols:

• Staff training in image acquisition;
• Minimum quality criteria;
• Retake rules;
• Handling ungradable cases.

In 2026, image quality becomes decisive, as AI and telemedicine depend on it.

5.3. Home and Remote Monitoring for Extended Treatment Regimens as eye care trends 2026

As treatment intervals lengthen, the risk of between-visit deterioration increases. Thus, 2026 strengthens the role of:

• Home functional monitoring;
• Digital questionnaires and symptom trackers;

Remote checkpoints signaling the need for earlier recall.

6. 2026 as the Year of Standardized Myopia Control and Greater Risk Awareness

By 2026, myopia control is no longer debated but formalized, grounded in consensus documents and systematic reviews. Myopia is increasingly recognized as a chronic disease with stages, phenotypes, and potentially blinding complications.

Implications for practice:

1. Focus on preventing progression to high myopia.
2. Combined strategies integrating behavioral, optical, and pharmacologic interventions with monitoring.
3. A shared language between optometrists and ophthalmologists, with coordinated patient pathways.
4. Support from AI and telemedicine for risk detection and personalized care.

Myopia control in 2026 becomes a structured, long-term risk-reduction process.

7. Optogenetics: Expanding the Evidence Horizon in Inherited Retinal Degenerations

In 2026, optogenetics moves beyond concept into longer-term observation. Publications from 2025 highlight functional stabilization or improvement in retinitis pigmentosa, emphasizing pragmatic success criteria.

For patients with severe vision loss, meaningful outcomes extend beyond visual acuity charts to spatial orientation, object recognition, and contrast sensitivity. In 2026, discussions increasingly focus on realistic endpoints and honest communication of limitations.

8. Less Invasive Interventions and Patient Comfort as Components of Clinical Effectiveness

Another key eye care trends 2026 is less traumatic technology that preserves efficacy while improving patient experience. A notable example is the FDA approval of Epioxa (epi-on) for keratoconus in 2025, preserving corneal epithelium and potentially reducing pain and recovery time.

This trend spans refractive surgery, ocular surface disease, and chronic condition management, reinforcing that patient experience is integral to adherence and clinical outcomes.

Conclusion

The ophthalmology trends 2026 clearly demonstrate that ophthalmology and optometry are entering a phase of mature transformation, where success is driven not by isolated innovations but by their integration into coherent clinical pathways. The focus is shifting from treating consequences to early detection, slowing progression, and long-term management of chronic eye disease.

Active treatment of geographic atrophy, photobiomodulation, extended anti-VEGF regimens, and the emergence of gene therapies for MacTel 2 and neovascular AMD fundamentally reshape patient management—from observation or frequent procedures to strategies aimed at preserving retinal structure and function with minimal procedural burden. These approaches require careful patient stratification and responsible expectation management, as the goal increasingly becomes slowing neurodegeneration rather than restoring vision.

At the diagnostic level, 2026 reinforces decentralization: portable devices, telemedicine, and autonomous AI bring screening closer to patients and enable coverage of much broader populations. Oculomics and AI transform ocular images into sources of digital biomarkers that may influence not only ophthalmic but also general clinical management. At the same time, it becomes clear that technological value is defined not by algorithms or devices, but by data quality, model validation, and clearly structured patient pathways—from screening to treatment.

Diabetic retinopathy screening and treatment: a complete guide

Table of Contents

1. What are the diabetic retinopathy screening methods?
2. Fundus images in DR screening
3. Can OCT detect diabetic retinopathy?
4. What does diabetic retinopathy look like on OCT?
5. What is optimal diabetic retinopathy screening frequency?
6. What is the best treatment for diabetic retinopathy?
7. Diabetic retinopathy management: key takeaways

Diabetic retinopathy (DR) remains the leading cause of irreversible vision loss among working-age adults worldwide. According to the International Diabetes Federation (IDF), one in three patients with diabetes shows signs of DR, and 10% develop diabetic macular edema (DME). Early diagnosis, systematic screening, and individualized monitoring are essential to prevent vision loss.

What are the diabetic retinopathy screening methods?

Modern methods of DR screening include:

• Telemedicine platforms – enable automated transmission of fundus images
• Mobile fundus cameras – Wi-Fi–enabled devices for field examinations
• Smartphone-based platforms – use specialized lenses for retinal imaging
• Optical coherence tomography (OCT) – used to detect early retinal changes and diabetic macular edema, complementing fundus photography
• AI-based systems –  solutions for automated image analysis for fundus and OCT

In practice, these methods are often combined. For example, patients may undergo fundus photography, after which images are sent to telemedicine centres and analysed by AI algorithms. More complex cases are then referred to ophthalmologists.

DR screening is frequently incorporated into annual diabetes check-ups conducted by primary care physicians trained in basic fundus photography. This approach, already successfully implemented in several EU countries, has reduced the incidence of severe DR.

Innovations in DR screening have broadened access for rural residents, older adults, and individuals with limited mobility. Integration into national e-health systems enables automated reminders and electronic medical record linkage, incorporating laboratory data (HbA1c, blood pressure) alongside retinal images.

Fundus images in DR screening

Fundus photography is the optimal primary screening method due to its high diagnostic yield, cost-efficiency, simplicity, and ability to integrate with AI and telemedicine solutions. 

It enables detection of microaneurysms, hemorrhages, exudates, and neovascularization, often before symptoms arise. National screening programs rely heavily on digital fundus imaging, which, when combined with AI, provides an efficient platform for mass DR detection.

Advances in fundus imaging for diabetic retinopathy have improved efficiency. Modern non-mydriatic cameras deliver high-quality images without pupil dilation, while automated image analysis supports rapid identification of suspicious cases. Cloud storage and telemedicine platforms facilitate remote evaluation, increasing coverage in regions with limited ophthalmology services.

Next-generation wide-field cameras further enhance detection by capturing peripheral pathology. Some devices also generate automated annotations, reporting lesion type, DR stage, and DME presence, thereby standardizing interpretation and expediting clinical decision-making.

Can OCT detect diabetic retinopathy?

Yes. OCT can detect early structural changes in the retina and is increasingly used to complement standard diabetic retinopathy screening.

• Role in DR screening – While not a primary screening tool, OCT is now widely applied alongside fundus photography. It is especially valuable for detecting early diabetic macular edema (DME) and subtle morphological changes in the central retina not visible during ophthalmoscopy.
  
• High-resolution imaging – OCT visualizes changes such as photoreceptor layer disruption, subclinical intraretinal fluid, neurosensory retinal thickening, and foveal edema. These findings often appear before clinically significant macular edema.
  
• Differential diagnosis – OCT also helps identify other causes of vision loss in diabetic patients, for example, ruling out age-related macular degeneration.
• Clinical evidence – Studies confirm that combining OCT with fundus photography increases diagnostic accuracy for DME. Experts therefore recommend this approach for patients with long-standing diabetes, poor glycemic control, or vision complaints.

What does diabetic retinopathy look like on OCT?

On OCT, diabetic retinopathy (DR) can appear as a combination of retinal structural damage, fluid accumulation, and microvascular changes that may not be visible on fundus photography.

Typical OCT findings in DR include:

• Photoreceptor damage – loss of outer retinal layers, especially the ellipsoid zone
• Intraretinal hyperreflective foci, hard exudates
• Microaneurysms – visible as small, round changes within the retina
• Retinal thickness changes and neuroepithelial layer atrophy
• Diabetic macular edema  – with intraretinal hyporeflective cystoid spaces and neuroepithelial swelling
• Subretinal fluid  – resulting from increased vascular permeability
• DRIL – disorganization of inner retinal layers, associated with poor prognosis
• Epiretinal membranes – potential precursors to retinal detachment

Advanced findings
OCT can also reveal proliferative changes and tractional zones, which may progress to tractional retinal detachment.

OCTA insights
Beyond structural analysis, OCT angiography (OCTA) allows visualization of retinal microvascular changes without the contrast injection. OCTA helps identify areas of neovascularization, capillary network disruption, and the degree of macular ischemia.

What is optimal diabetic retinopathy screening frequency?

The screening frequency for diabetic retinopathy is tailored to diabetes type, disease stage, and risk factors:

Type 1 diabetes

• First screening: 3–5 years after diagnosis (due to onset in children and young adults)
• Then annually, if no DR is detected
• If DR is present, frequency depends on severity

Type 2 diabetes

• Screening at diagnosis, as DR may already be present.
• If no DR, repeat every 1–2 years.

Patients with confirmed DR

• No visible DR, mild non-proliferative diabetic retinopathy (NPDR), no DME — every 1–2 years
• Moderate NPDR — every 6–12 months.
• Severe NPDR — every 3 months.
• Proliferative DR (PDR) — monthly, with regular OCT monitoring of the macula.
• DME — monthly if center-involving, every 3 months if not.

Pregnant women with type 1 or type 2 diabetes

• Screening before conception or in the first trimester, with follow-up each trimester and postpartum
• Screening is not required for gestational diabetes without pre-existing diabetes

Post-treatment patients (laser or vitrectomy)

• Typically, every 3–6 months during the first year, individualized based on retinal stability

Monitoring of diabetic retinopathy progression

Ongoing diabetic retinopathy monitoring is essential to detect early signs of progression and guide treatment decisions. A key focus in monitoring is diabetic macular edema (DME), which represents fluid accumulation in the macula due to leakage from damaged retinal vessels. DME is a common complication of DR and the leading cause of vision loss in diabetic patients. OCT plays a central role in detecting DME and identifying structural changes that indicate disease progression.

OCT biomarkers in DME

OCT enables precise visualization of retinal layers with micron resolution, confirming DME presence and providing prognostic biomarkers for treatment selection and monitoring. 

The main OCT biomarkers in DME include:

• Cystoid hyporeflective intraretinal spaces – usually in the inner nuclear layer (INL) or outer plexiform layer (OPL). Their number, size, and location correlate with edema severity. Large or confluent spaces may indicate chronicity and a worse prognosis.
• Subretinal fluid – accumulation between the neurosensory retina and retinal pigment epithelium. Often associated with a better visual prognosis, but requires close monitoring and consideration in anti-VEGF therapy.
• Central macular thickening – a key marker of treatment effectiveness and disease activity.

OCT red flags in DR progression

Beyond DME, OCT helps identify broader signs of DR worsening that require therapy reassessment:

• Progressive central macular thickening despite treatment
• Increase in intraretinal or subretinal fluid, or enlargement of cystoid spaces
• New hyperreflective foci, reflecting inflammatory activity (these may precede hard exudates or RPE changes)
• Development or progression of disorganization of inner retinal layers (DRIL), an independent predictor of poor prognosis, even when orphological improvement is seen on OCT
• Ellipsoid zone disruption, indicating photoreceptor damage
• Signs of macular ischemia, although better evaluated with OCTA, indirect signs on OCT may include thinning of the inner retinal layers.
• Tractional changes, such as epiretinal membranes, inner retinal stretching, or macular traction

The appearance of these OCT features should prompt clinicians to reconsider therapy, whether by switching anti-VEGF agents, introducing steroids, using combination therapy, or referring patients for surgical evaluation when traction is present.

What is the best treatment for diabetic retinopathy?

The treatment of diabetic retinopathy is based on a comprehensive approach that takes into account not only the disease stage, but also individual patient characteristics, OCT findings, comorbidities, and prognostic biomarkers. Modern strategies combine preventive, pharmacological, and surgical methods, as well as personalized medicine tools based on retinal imaging.

Criteria for treatment selection

The choice of therapy is guided by the following parameters:

• DR stage –  non-proliferative, proliferative, with or without DME
  
• Form of macular edema –  focal, diffuse, with or without subretinal fluid
  
• Presence of DRIL, EZ disruption, ischemic changes on OCTA
  
• Response to previous treatment –  anti-VEGF, steroids, laser
  
• Comorbidities –  renal insufficiency, hypertension, poor adherence

For low-risk patients, observation or focal laser may be sufficient. Patients with significant DME usually require anti-VEGF or steroid injections. Those with proliferative DR often undergo panretinal laser photocoagulation or vitrectomy.

Diabetic retinopathy treatment methods

The main treatment options for diabetic retinopathy include pharmacotherapy, laser therapy, surgical intervention, and personalized approaches based on OCT.

1. Pharmacotherapy: anti-VEGF and steroids

Anti-VEGF agents such as aflibercept, ranibizumab, and bevacizumab are the first-line therapy for diabetic macular edema. They are especially effective in patients with pronounced edema and without ischemia.

New drugs with extended duration of effect, including port delivery systems, are becoming available.

Steroids are used when DME is persistent, when patients do not respond to anti-VEGF therapy, or in cases with an inflammatory phenotype.

2. Laser therapy

Injections have largely replaced laser therapy in the treatment of DME. However, panretinal photocoagulation remains the standard treatment for proliferative DR.

Subthreshold micropulse laser is increasingly applied for focal edema, as it minimizes tissue damage.

3. Surgical treatment

Vitrectomy is recommended in cases of tractional macular edema, vitreous hemorrhage, or retinal detachment.

4. Personalization with OCT

Modern treatment protocols use OCT biomarkers to tailor therapy and improve prognosis.

Patient education and multidisciplinary care

DR treatment outcomes strongly depend on adherence. Patients must be informed about the need for regular injections, monitoring, and systemic control. Coordinated care involving ophthalmologists, endocrinologists, and family doctors helps maintain stable glycemic control and slows DR progression.

Diabetic retinopathy management: key takeaways

Diabetic retinopathy is a progressive disease, but modern diagnostics and treatments make it possible to preserve vision and improve outcomes. OCT and OCTA have become essential tools for early detection, risk assessment, and personalized therapy planning. Effective management combines pharmacotherapy, laser treatment, surgery, and patient education. Multidisciplinary care and strong patient adherence remain crucial for long-term success. With timely monitoring and tailored treatment, the progression of diabetic retinopathy can be significantly slowed.

Disclaimer: USA FDA 510(k) Class II; Altris Image Management System (Altris IMS); AI/ML models and components intended to use for research purposes only, not for clinical diagnosis purposes.

22.08.2025

Altris Achieves MDSAP Certification, Strengthening Global Presence and Clinical Credibility

Altris Inc., a leading decision support platform for OCT scan analysis, proudly announces that it has passed the Medical Device Single Audit Program (MDSAP) audit. 

Based on the objective evidence reviewed, this audit enables a recommendation for Initial certification to ISO 13485:2016 MDSAP, including the requirements of Australia, Brazil, Canada, the USA, and Japan, and EU 2017/745, and that the scope was reviewed and found to be appropriate for ISO 13485:2016/MDSAP and EU MDR 2017/745.

The results of this audit are suitable for obtaining the EU MDR 2017/745 certificate, which we are currently in the process of pursuing.

ISO 13485:2016/MDSAP enables Altris Inc. to “design, manufacture, and distribute medical software for the analysis and diagnosis of retinal conditions globally.” It is recognized by leading global health regulators and signals trust and credibility to public and private hospitals, eye care networks, and optometry chains worldwide. 

MDSAP Certification also opens the door for Altris Inc. to enter new international markets, including Asia-Pacific, Latin America, and additional parts of North America. The MDSAP certification allows a single regulatory audit of Altris AI’s Quality Management System (QMS) to be recognized by multiple major health authorities, including:

• FDA (United States)
• Health Canada
• TGA (Australia)
• ANVISA (Brazil)
• MHLW/PMDA (Japan)

MDSAP enforces that the Quality Management System for developing, testing, and maintaining AI Decision Support for OCT complies with international medical device standards. Altris AI Decision Support for OCT Analysis system that facilitates the detection and monitoring of over 70 retinal pathologies and biomarkers, including early signs of glaucoma, diabetic retinopathy, and age-related macular degeneration. 

“Achieving ISO 13485:2016 certification under the stringent MDSAP requirements is a significant accomplishment for our team,” said Maria Znamenska, MD, PhD, Chief Medical Officer at Altris AI. “As a practicing ophthalmologist, I understand that the safety of patients is the absolute priority. Especially when implementing such an innovative technology as AI for decision support in OCT analysis. That is why we did everything possible to build quality processes that guarantee the highest level of safety for the patients.

This certification enables Altris AI to expand its presence and offer eye care specialists upgraded functions such as GA progression monitoring, flags for smart patient filtering, or automated drusen count.”

“This is more than a regulatory milestone for our team  – it’s a signal to the global eye care community that Altris AI is a trusted clinical partner,” said Andrey Kuropyatnyk, CEO of Altris AI. 

About Altris 

Founded in 2017, Altris AI is at the forefront of integrating artificial intelligence analysis into ophthalmology and optometry.

The company’s platform is designed to assist eye care professionals in interpreting OCT scans with greater objectivity and make informed treatment decisions. It’s a vendor-neutral platform compatible with OCT devices from 8 major global manufacturers. With a commitment to innovation and compliance, Altris AI continues to develop solutions that set higher standards in the eye care industry and improve patient outcomes.

Disclaimer: USA FDA 510(k) Class II; Altris Image Management System (Altris IMS); AI/ML models and components intended to use for research purposes only, not for clinical diagnosis purposes.

Glaucoma OCT Monitoring Guide: From Detection to Long-Term Care

Table of Contents

1. Glaucoma detection: why early diagnosis is critical
2. How to detect glaucoma in early stages: key approaches
3. Advanced imaging for glaucoma: OCTA
4. OCT glaucoma monitoring after diagnosis
5. Additional tools for monitoring glaucoma treatment
6. Glaucoma OCT: the foundation of long-term glaucoma care

Optical Coherence Tomography (OCT) has fundamentally changed glaucoma diagnostics over the past two decades. It enables non-invasive, micron-level imaging of retinal microstructures and provides objective measurements of the retinal nerve fibre layer (RNFL), ganglion cell complex (GCC), and optic nerve head (ONH) parameters. Moreover, the advent of OCT angiography (OCTA) has introduced a new dimension in assessing microcirculation—complementing structural analysis and potentially predicting glaucoma progression.

Today,  OCT is the standard for early detection, monitoring, and risk stratification of glaucoma progression, as recognised in international clinical guidelines. When combined with functional tests, tonometry, and anterior chamber angle assessment, OCT becomes the foundation for personalised glaucoma management.

Glaucoma detection: why early diagnosis is critical

Early glaucoma diagnosis is vital, as optic nerve damage caused by the disease is irreversible. Many patients seek care only after significant vision loss has occurred, at which point treatment may slow progression but cannot restore lost function. This is why ophthalmologists emphasise the importance of glaucoma detection at preclinical or pre-perimetric stages.

How does OCT help in early glaucoma detection?

OCT provides high-resolution imaging of the retina and optic nerve head. Unlike subjective functional tests, OCT delivers objective, quantitative data on ganglion cells, nerve fibre layers, and the neuroretinal rim, enabling recognition of even subtle structural changes.

Recent OCT models go further, allowing detailed visualisation of the lamina cribrosa, a structure known to be altered in glaucoma. Today, OCT is recognised as a key diagnostic tool in the guidelines of both the European Glaucoma Society and the American Academy of Ophthalmology.

How to detect glaucoma in early stages: key approaches

Early glaucoma detection relies on evaluating structural and functional parameters of the eye, supported by advanced imaging techniques. The three main parameters assessed with glaucoma OCT are:

• Ganglion Cell Complex (GCC) thickness and asymmetry
• Retinal Nerve Fibre Layer (RNFL) thickness
• Optic nerve head parameters with the DDLS scale

In addition, OCT Angiography (OCTA) provides complementary insights into ocular microvasculature that may indicate early glaucomatous damage.

Glaucoma detection parameter 1: GCC thickness and asymmetry

One of the most sensitive preclinical biomarkers of glaucomatous damage is thinning of the ganglion cell complex (GCC), which includes the ganglion cell layer (GCL), inner plexiform layer (IPL), and macular RNFL (mRNFL). It is assessed through macular OCT scans. Damage in this area is particularly critical, as 50–60% of all ganglion cells are concentrated within the central 6 mm zone.

Assessing asymmetry between the superior and inferior halves of the macula within the GCC is a key diagnostic indicator. Studies show that minimum GCC thickness and FLV/GLV indices (Focal Loss Volume / Global Loss Volume) are predictors of future RNFL thinning or emerging visual field defects. Asymmetry maps significantly ease clinical interpretation.

A newer approach—vector analysis of GCC loss—also allows clinicians to visualise the direction of damage, which often correlates with future visual field defects.

Glaucoma detection parameter 2: RNFL thickness analysis

RNFL analysis is among the most widely used glaucoma diagnostic methods. The RNFL reflects the axons of the ganglion cells and is readily measured in optic nerve scans. Temporal sectors are the most sensitive and often show the earliest changes.

Even when the overall thickness appears normal, localised defects should raise suspicion. Sectoral thinning of ≥5–7 μm is considered statistically significant. Age-related RNFL decline (~0.2–0.5 μm/year) must also be considered.

Glaucoma detection parameter 3: optic nerve head parameters and the DDLS scale

Evaluating the optic nerve head (ONH) is essential. OCT enables automated assessment of optic disc area, cup-to-disc ratio (C/D), cup volume, rim area, and the lamina cribrosa.

The Disc Damage Likelihood Scale (DDLS) classifies glaucomatous ONH changes based on the thinnest radial rim width or, if absent, the extent of rim loss. Unlike the C/D ratio, DDLS adjusts for disc size. When combined with OCT, DDLS significantly enhances objective clinical assessment.

In high myopia, automatic ONH segmentation often misclassifies anatomy. Here, newer deep learning–based segmentation models improve accuracy.

Advanced imaging for glaucoma: OCTA

OCT Angiography (OCTA), an advanced glaucoma OCT technique, provides unique insights into ocular circulation. It enables evaluation of:

• Vessel density in the peripapillary region
• Optic nerve and macular vascularisation
• Retinal versus ONH perfusion in both eyes

Studies confirm that reduced vessel density correlates with RNFL loss and visual field deterioration, and often precedes both.

OCT glaucoma monitoring after diagnosis

Glaucoma can progress even with stable intraocular pressure (IOP), making regular structural assessment of the optic nerve and inner retina crucial for therapy adjustment.

Glaucoma OCT is not only a diagnostic tool but also the primary method for monitoring glaucomatous damage. Unlike functional tests, OCT can detect even minimal RNFL or GCL thinning months or even years before visual field loss appears. With serial measurements and built-in analytics, OCT allows clinicians to track glaucoma progression rates and identify high-risk patients.

Methods for glaucoma progression monitoring

There are two main approaches to monitoring glaucoma progression with OCT:

Method 1: event-based analysis

This method compares current scans with a reference baseline, identifying whether RNFL or GCL thinning exceeds expected variability.

? Example: Heidelberg Eye Explorer (HEYEX) highlights suspicious areas in yellow (possible loss) or red (confirmed loss).

Limitations include sensitivity to artifacts, image misalignment, and segmentation quality. A high-quality baseline scan is essential.

Method 2: trend-based analysis

This approach accounts for time. The software plots RNFL/GCL thickness trends over time in selected sectors or globally and calculates the rate of progression.

Examples:

• RNFL thinning >1.0 μm/year is clinically significant.
• Thinning >1.5 μm/year indicates active progression.

It also accounts for age-related changes, helping differentiate physiological vs. pathological decline.

Visual assessment in glaucoma OCT

Qualitative analysis also plays an important role in detecting glaucoma progression. Key aspects include:

• Focal RNFL thinning (localised defects)
• Changes in the neuroretinal rim
• Alterations in ONH cupping
• GCL/GCIPL comparison (superior vs. inferior) on macular maps
• New segmentation artifacts (may mimic progression)

OCT glaucoma findings that indicate true progression

Five OCT findings suggest true glaucomatous progression:

1. RNFL thinning >10 μm in one sector or >5 μm in several sectors
2. New or worsening GCL asymmetry (yellow to red colour shift)
3. Emerging or expanding RNFL defects on colour maps
4. Increasing C/D ratio with concurrent rim thinning
5. New localised areas of vessel density loss on OCTA

Particular attention should be paid to the inferotemporal and superotemporal RNFL sectors, where 80% of early changes occur.

Frequency of glaucoma OCT monitoring

According to the AAO and EGS, the recommended frequency for OCT glaucoma monitoring is:

• High-risk patients: every 6 months
• Stable patients: once a year
• For trend analysis: at least 6–8 scans over 2 years to ensure statistical reliability

Looking ahead, broader use of AI for glaucoma is expected to support earlier and more accurate detection, while also reducing false positives.

Additional tools for monitoring glaucoma treatment

While glaucoma OCT is essential for detecting structural changes, a comprehensive glaucoma assessment requires a multimodal approach. Additional tools include perimetry, tonometry, optic disc fundus photography, and gonioscopy.

Perimetry (visual field testing)

Functional assessment of the optic nerve remains crucial. Standard Automated Perimetry (SAP), most often performed with Humphrey Visual Field Analyzer protocols (24-2, 30-2, 10-2), is the most widely used method.

Key indices:

• MD (mean deviation): average deviation from normal values
• PSD (pattern standard deviation): highlights localised defects
• VFI (visual field index): summarises global visual function; useful for tracking glaucoma progression
• GHT (glaucoma hemifield test): automated analysis of field asymmetry

? Important: In 30–50% of cases, structural changes such as RNFL thinning on OCT precede visual field defects; in others, functional loss appears first. Best practice relies on integrated OCT and perimetry to correlate damage location and monitor glaucoma progression more precisely.

Combined OCT and perimetry remains the gold standard for progression monitoring.

Tonometry

Intraocular pressure (IOP) is the only clearly modifiable risk factor associated with both glaucoma onset and progression.

• Goldmann applanation tonometry remains the gold standard.
• A single IOP reading is insufficient — diurnal fluctuations are an independent risk factor, particularly in normal-tension glaucoma.

Optic disc fundus photography

Although subjective, fundus imaging remains valuable for documenting glaucomatous changes, especially in borderline cases. Unlike OCT, it does not provide quantitative data but helps visualise morphology over time.

What to assess:

• Progressive disc cupping
• Changes in neuroretinal rim shape or colour
• Disc margin haemorrhages (linked to faster RNFL thinning and visual field loss)
• Inter-eye comparisons

Gonioscopy

Gonioscopy evaluates the anterior chamber angle and helps exclude angle-closure, pigmentary, or pseudoexfoliative glaucoma. It also identifies:

• Neovascularisation
• Trabecular meshwork abnormalities
• Other angle anomalies

Patient education: a key to successful glaucoma management

Accurate glaucoma detection and therapy are not enough; adherence to monitoring and treatment is equally critical.

The challenge:

• Early-stage glaucoma is asymptomatic.
• Many patients underestimate its seriousness, leading to poor compliance, missed follow-ups, and discontinuation of therapy.

The goals of patient education:

• Explain that glaucoma progresses silently but can lead to irreversible blindness if untreated.
• Use real-life examples (before/after OCT scans, visual field comparisons) to illustrate progression.
• Teach patients to recognise warning signs (vision changes, eye pain).
• Visualise disease progression with AI tools showing RNFL loss and future risk.

Educational resources may include:

• Printed brochures in patient-friendly language
• Videos featuring OCT images with explanations
• Doctor–patient in-clinic discussions
• Telemedicine platforms with reminders and follow-up prompts

According to the AAO, patients who understand glaucoma are 2.5 times more likely to adhere to treatment and attend check-ups.

Glaucoma OCT: the foundation of long-term glaucoma care

Glaucoma OCT now plays a central role in both diagnosis and monitoring. Its ability to detect subtle structural changes before measurable functional loss makes early intervention possible and increases the chances of preserving vision.

But technology alone is not enough. Accurate interpretation, combined with strong patient education, is essential. When patients understand their disease and the role of glaucoma OCT in treatment, adherence improves and outcomes are better.

OCT is not just a diagnostic device; it is the cornerstone of an integrated glaucoma management strategy, from initial screening to long-term monitoring and treatment optimisation.

Disclaimer: USA FDA 510(k) Class II; Altris Image Management System (Altris IMS); AI/ML models and components intended to use for research purposes only, not for clinical diagnosis purposes.

Dry AMD Treatment: Modern Ways to Slow Progression

Table of Contents

1. What are the dry macular degeneration treatment breakthroughs?
2. How to monitor dry AMD progression with OCT?
3. What are the challenges of dry age-related macular degeneration monitoring?
4. How do I organize efficient dry AMD monitoring in my clinic?
5. Why are optometrists on the front line of early AMD detection?
6. How can OCT insights help support patients emotionally?
7. Conclusion

For many years, dry or non-exudative AMD was seen as untreatable. Most research focused on wet AMD and anti-VEGF therapy.

Today, this paradigm is shifting. Around 30% of patients with age-related macular degeneration are affected by the dry form, which makes finding effective therapies critical. Recently, the first FDA-approved drugs for dry macular degeneration injections have appeared, offering hope to patients with geographic atrophy (GA). Alongside, new physiotherapeutic methods, such as multi-wavelength photobiomodulation, are showing promising results.

Geographic atrophy (GA) is an advanced, irreversible form of dry AMD. It occurs when parts of the retina undergo cell death, leading to progressive vision loss. But even the best dry AMD treatment is incomplete without objective measurement. That’s where modern tools for macular degeneration monitoring come in, and optical coherence tomography (OCT) is now at the core of this process.

What are the dry macular degeneration treatment breakthroughs?

The latest dry macular degeneration treatment breakthroughs include:

• Multiwavelength photobiomodulation
• FDA-approved injectable drugs
• AREDS 2-based supplements

In the past, recommendations focused only on reducing risks — quitting smoking, managing blood pressure, and eating a healthy diet.
Now, new approaches to dry AMD treatment combine prevention with active therapies to slow AMD progression and especially the advance of GA.

1. Dry AMD treatment using multiwavelength photobiomodulation

Multiwavelength photobiomodulation for AMD is a promising new treatment. It uses specific red and near-infrared light wavelengths (~590–850 nm) and helps reduce oxidative stress, inflammation, and pigment epithelial cell death.

One of the best-known systems is Valeda Light Therapy, which delivers controlled multiwavelength light directly to the retina.

The LIGHTSITE III clinical trial showed that photobiomodulation can slow the decline in visual acuity and reduce the rate of GA expansion.

Limitations:

• Only 3–5 years of long-term data available
• Requires costly equipment and training
• Effectiveness in late-stage GA remains unclear

2. Dry AMD treatment using FDA-approved injectable drugs

AMD injection drugs approved by the FDA include Izervay and Syfovre.

• Izervay (avacincaptad pegol): A C5 complement protein inhibitor that targets the complement cascade involved in chronic retinal inflammation and damage. Izervay, approved for geographic atrophy secondary to dry AMD, has demonstrated a reduced rate of GA progression in clinical trials.
• Syfovre (pegcetacoplan): A C3 complement inhibitor that blocks the central component of the complement system to reduce inflammation. Syfovre is the first FDA-approved treatment for GA that targets complement component C3, showing a clinically meaningful slowing of GA progression.

Both dry macular degeneration injections have shown the ability to slow GA progression compared to placebo. Although they do not restore vision, slowing vision loss is a meaningful clinical outcome.

Key considerations for injections:

• Administered intravitreally, usually monthly or every other month
• Require doctor training and patient education on risks (e.g., endophthalmitis, increased intraocular pressure)
• Cost and access may limit use

3. Dry AMD treatment using AREDS 2-based supplements

AREDS 2 supplements are antioxidant supplements containing lutein, zeaxanthin, vitamins C and E, zinc, and copper. They can reduce the risk of progression to late-stage AMD by around 25% over five years, according to the AREDS 2 study.

Pros:

• Widely available
• Safe, with low side effect risk
• Supported by strong clinical evidence

Cons:

• Do not directly treat GA
• Cannot replace active therapies such as dry macular degeneration injections or photobiomodulation

How to monitor dry AMD progression with OCT

Effective macular degeneration monitoring relies on OCT. It is the gold standard for tracking retinal changes and predicting GA development.
Without OCT, clinicians are essentially “flying blind” when assessing AMD progression.

Key monitoring parameters of AMD progression

The key monitoring parameters of AMD progression include GA area, drusen, and distance to fovea.

1. GA area

This is the main metric when using intravitreal eye injections. Modern OCT systems provide GA measurements in mm², allowing doctors to objectively track changes over time.

Even if patients don’t notice symptoms, a growing GA area signals disease progression. In FDA trials for Syfovre and Izervay, the GA area was the primary endpoint.

2. Drusen

Drusen vary in number, size, and shape. A reduction or disappearance of drusen on OCT may seem like an improvement, but could actually indicate a transition to the atrophic stage. Regular monitoring helps detect this early.

3. Distance to fovea

The closer GA is to the fovea, the greater the risk of sudden vision loss.

Early detection enables:

• Referral to an ophthalmologist
• Timely conversations about potential vision loss

OCT outputs for AMD progression monitoring and communication

Useful OCT outputs for AMD progression monitoring and communication are heat maps and progress charts.

1. Heat maps

Modern OCT systems use color-coded heat maps to show pigment epithelium thickness and drusen distribution. This visual format helps in several ways:

• Makes interpretation easier for clinicians
• Helps patients better understand their condition
• Encourages patients to stay engaged with treatment

In clinical practice, it serves as a highly effective communication tool.

2. Progress charts

Most OCT systems can compare results across visits

• For doctors: Helps guide treatment decisions
• For patients: Provides visual proof of stabilization or worsening

The role of objective evidence in patient treatment

Patients may question the value of long-term treatments or costly procedures.

OCT is the gold standard for patient motivation. When patients see actual changes, they’re more likely to agree to treatment.

What are the challenges of macular degeneration monitoring?

Monitoring dry AMD presents technical, organizational, and psychological challenges. Doctors of all levels of experience should be aware of them.

1. Invisible microchanges

Early atrophy or drusen changes may be subtle. Patients may not notice them due to eccentric fixation or slow adaptation.

Without OCT, doctors may miss early GA, delaying treatment.

It is necessary to perform OCT even when there are only minor changes in visual acuity or if the patient reports image distortion (metamorphopsia).

2. Subjective assessment

Ophthalmoscopy reveals only obvious changes. Subtle drusen or early atrophy might be missed.

Relying on patients’ complaints is risky — many don’t notice issues until it’s too late.

That’s why even small optical practices should establish clear referral pathways for OCT exams.

3. Unnecessary referrals

Optometrists or primary care doctors often refer patients to ophthalmologists “just in case,” because they don’t have access to OCT or lack experience interpreting it.

This puts unnecessary strain on specialists. In many cases, nothing new is done after the exam because there are no previous images for comparison.

4. Limitations of OCT devices

Not all OCT devices measure GA or track drusen equally well. Older models may lack automated measurements of atrophy area.

In some cases, referral to a center with advanced OCT is necessary.

How do I organize efficient dry AMD monitoring in my clinic?

Practical tips:

1. Create a baseline chart with OCT images during the first visit.

2. Monitor regularly:

• Every 6–12 months in the early stages
• Every 3–6 months with GA
• Before each intravitreal injection

3. Standardise scanning protocols to minimise variability.

4. Use OCT software tools for image comparison, GA calculation, heat maps.

5. Communicate clearly with patients about drusen, atrophy, and treatment goals.

Why are optometrists on the front line of early AMD detection?

Optometrists play a key role in spotting the early signs of AMD, as they are often the first point of contact in eye care.

They perform initial screenings, provide guidance on lifestyle and supplements, and ensure regular OCT monitoring.

If drusen, pigment epithelial changes, or signs of GA are present, they refer patients to ophthalmologists for confirmation and treatment planning.

How can OCT insights help support patients emotionally?

Patients with dry AMD often ask: “Why bother if it can’t be cured?”
Here, OCT plays an emotional as well as clinical role. Showing OCT scans can:

• Prove the value of slowing AMD progression
• Emphasise patients’ role in preserving sight
• Reassure them that long-term care makes a difference

Dry macular degeneration treatment breakthroughs: key takeaways for slowing AMD progression

Modern dry macular degeneration treatment breakthroughs, including FDA-approved injections, photobiomodulation, and AREDS 2 supplements,  have changed the outlook for patients.
Yet treatment alone is not enough. Without consistent macular degeneration monitoring using OCT, the benefits of these therapies may be lost.

The future of dry AMD treatment lies in a partnership between optometrists, ophthalmologists, and patients. Together, with breakthrough therapies and precise monitoring, we can slow AMD progression and give patients the best chance of preserving vision.

Disclaimer: USA FDA 510(k) Class II; Altris Image Management System (Altris IMS); AI/ML models and components intended to use for research purposes only, not for clinical diagnosis purposes.

Disclaimer: In the USA, Altris Image Management System (Altris IMS) has USA FDA 510(k) Class II clearance; AI/ML models and components are intended to use for research purposes only, not for clinical diagnosis purposes.

AI for Decision Support with OCT: An Interview with Clara Pereira, Optometrist from Franco Oculista

About Franco Oculista Optometry in Portugal.

Franco Oculista is the optometry center with a 70-year-old history: its roots date back to the mid-1950s in Luanda, where it was founded by Gonçalo Viana Franco. Having left behind a career in pharmacy, Gonçalo pursued his entrepreneurial vision by opening an optician’s bearing his name in the heart of the Angolan capital. Driven by a thirst for knowledge and a deep sense of dedication, he turned his dream into reality. With a commitment to professionalism and a forward-thinking approach, he integrated the most innovative technologies available at the time. This blend of passion, expertise, and innovation established Franco Oculista as a benchmark for quality and excellence in the field. In 1970s, the family returned to Portugal and opened the new FRANCO OCULISTA space on Avenida da Liberdade.

How do Franco Oculista describe their mission?

“Through individualized and segmented service, we seek to respond to the needs of each client. We combine our knowledge with the most sophisticated technical equipment and choose quality and reliable brands. We prioritize the evolution of our services and, for this reason, we work daily to satisfy and retain our customers with the utmost professionalism.”

Clara Pereira is one of the optometrists at Franco Oculista and has been an optometrist for nearly two decades. Based in a private clinic in Portugal, she brings years of experience and calm confidence to her consultations. We talked with her to learn how her clinical practice has evolved, particularly since integrating OCT and, more recently, Altris AI – AI for Decision Support with OCT.

Altris AI: Clara, can you tell us a bit about your daily work?

Clara: “Of course. I’ve been working as an optometrist for 19 years now. My practice is quite comprehensive—I assess refractive status, binocular vision, check the anterior segment with a slit lamp, measure intraocular pressure, and always examine the fundus.

Clara: “In Portugal, we face limitations. We’re not allowed to prescribe medication or perform cycloplegia, so imaging becomes crucial. I rely heavily on fundus photography and OCT to guide referrals and detect early pathology.”

Altris AI: How central is OCT diagnostics to your workflow?
Clara: “OCT is substantial. I perform an OCT exam on nearly every patient, on average, eight OCT exams per day. It’s an essential part of how I gather information. With just one scan, I can learn so much about eye health.”

Altris AI: What kind of conditions do you encounter most frequently?
Clara: “The most common diagnosis is epiretinal membrane—fibrosis. But I also manage patients with macular degeneration and other retinal pathologies. Having the right tools is key.”

Altris AI: And what OCT features do you use the most?
Clara: “I regularly use the Retina, Glaucoma, and Macula maps. But if I had to choose one, the Retina Map gives me the most complete picture. It’s become my go-to.”

Altris AI: You’ve recently started using Altris AI. What has that experience been like?
Clara: “At first, I didn’t know much about it. But when Optometron introduced Altris AI to me—a company I trust—I didn’t hesitate. And I’m glad I didn’t. From the beginning, it felt like a natural extension of my clinical reasoning.

Clara: “Altris AI gives me an extra layer of certainty. It helps me extract more from the OCT images. I usually interpret the scan myself first, and then I run it through the platform. That way, I validate my thinking while also learning something new.”

Altris AI: Have any standout cases where Altris AI made a difference?

Clara: “Yes. I’ve had a few. One was a case of advanced macular degeneration, in which the AI visualization really helped me explain the condition to the patient. Another was using anterior segment maps for fitting scleral lenses—Altris was incredibly useful there, too. I do a lot of specialty lens fittings, so that was a big advantage.”

Altris AI: Would you recommend Altris AI to your colleagues?

Clara: “I would recommend Altris AI to my colleagues. For me, it’s about more than just the diagnosis. It’s about feeling confident that I’m seeing everything clearly and giving my patients the best care possible. Altris AI helps me do exactly that.”

Why This Matters: Altris AI in Real Practice

Clara’s story reflects the real value of AI in optometry—not as a replacement for clinical judgment, but as a powerful companion. With every OCT scan, she strengthens her expertise, improves diagnostic accuracy, and gives her patients the reassurance they deserve.

Whether identifying early signs of fibrosis, supporting complex scleral lens fittings, or acting as a second opinion, Altris AI seamlessly fits into the modern optometrist’s workflow, making every scan more meaningful.

AI for Decision Support with OCT: Transforming Retinal Diagnostics

Artificial Intelligence (AI) is revolutionizing the field of ophthalmology, particularly through its integration with Optical Coherence Tomography (OCT). OCT is a non-invasive imaging technique that captures high-resolution cross-sectional images of the retina, enabling early detection and monitoring of various ocular conditions. However, interpreting these scans requires time, expertise, and consistency—factors that AI-based decision support systems are uniquely positioned to enhance.

Altris AI (AI for OCT decision support platform) analyzes thousands of data points across B-scans, automatically detecting retinal pathologies, quantifying biomarkers, and identifying patterns that may be subtle or overlooked by the human eye. By providing objective, standardized assessments, Altris AI reduces diagnostic variability and improves clinical accuracy, especially in busy or high-volume practices.

For optometrists and ophthalmologists, AI acts as a second opinion, flagging early signs of diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma. It streamlines workflows by highlighting areas of concern, prioritizing cases that require urgent attention, and offering visual explanations that are easy to communicate to patients.

Moreover, Altris AI enableS longitudinal tracking of pathology progression. By comparing OCT scans over time ( even from various OCT devices), clinicians can monitor subtle changes in drusen volume, retinal thickness, supporting timely clinical decisions and tailored treatment strategies. The integration of AI into OCT interpretation not only enhances diagnostic confidence but also supports evidence-based care, early intervention, and improved patient outcomes. As AI continues to evolve, it will play a vital role in advancing precision medicine in ophthalmology, empowering eye care professionals with tools that are fast, reliable, and scalable.

In essence, AI for OCT decision support is not replacing clinical expertise; it is augmenting it, elevating the standard of care through speed, accuracy, and actionable insights.

Future of Ophthalmology: 2025 Top Trends

In a recent survey conducted by our team, we asked eye care specialists to identify the most transformative trends in ophthalmology by 2025. The results highlighted several key areas, with artificial intelligence (AI) emerging as the clear frontrunner, cited by 78% of respondents.

However, the survey also underscored the significant impact of optogenetics, novel AMD/GA therapies, and the continuing evolution of anti-VEGF treatments. This article will explore the practical implications of these advancements, providing an overview of how they are poised to reshape diagnosis, treatment, research, and, ultimately, patient outcomes in ophthalmology.

In this article, we will also discuss Oculomics, a very promising field that is gaining momentum.

Top AI Technology for Detecting Eye-related Health Risks 2025

Building upon the survey’s findings, we begin with the most prevalent trend: top AI technology for detecting eye-related health risks in 2025

AI in Clinical Eye Care Practice

With the increasing prevalence of conditions like diabetic retinopathy and age-related macular degeneration, there is a growing need for efficient and accurate screening tools. And AI is already valuable for eye-care screening: algorithms can analyze retinal images and OCT scans to identify signs of these diseases, enabling early detection and timely intervention.

Source

AI-powered screening tools can also help identify rare inherited retinal dystrophies, such as Vitelliform dystrophy and Macular telangiectasia type 2. These conditions can be challenging to diagnose, but AI algorithms can analyze retinal images to detect subtle signs that human observers may miss.

AI also starts to play a crucial role in glaucoma management. Early detection of glaucoma demands exceptional precision, as the early signs are often subtle and difficult to detect. Another significant challenge in glaucoma screening is the high rate of false positive referrals, which can lead to unnecessary appointments in secondary care and cause anxiety for patients, yet delayed or missed detection of glaucoma results in irreversible vision loss for millions of people worldwide. So, automated AI-powered glaucoma analysis can offer transformative potential to improve patient outcomes.

This OD module evaluates optic disc parameters using OCT, providing personalized assessments by accounting for individual disc sizes and angle of rim absence. Such a tailored approach eliminates reliance on normative databases, making evaluations more accurate and patient-specific.

Furthermore, it enables cross-evaluation across different OCT systems, allowing practitioners to analyze macula and optic disc pathology, even when data originates from multiple OCT devices. Key parameters evaluated by Altris AI’s Optic Disc Analysis include disc area, cup area, cup volume, minimal and maximum cup depth, cup/disc area ratio, rim absence angle, and disc damage likelihood scale (DDLS).

AI for Clinical Trials and Research

AI is revolutionizing clinical trials and research in ophthalmology. One such key application of AI is biomarker discovery and analysis. Algorithms can analyze large datasets of medical images, such as OCT scans, to identify and quantify biomarkers for various eye diseases. These biomarkers can be used to assess disease progression, monitor treatment response, and predict clinical outcomes.

AI is also being used to improve the efficiency and effectiveness of clinical trials. By automating the process of identifying eligible patients for clinical trials, AI can help researchers recruit participants more quickly and ensure that trials include appropriate patient populations, accelerating the development of new treatments.

Algorithms can analyze real-world data (RWD) collected from electronic health records and other sources to generate real-world evidence (RWE). RWE provides valuable insights into disease progression, treatment patterns, and long-term outcomes in everyday clinical settings, complementing the findings of traditional randomized controlled trials.

Oculomics

Integrating digitized big data and computational power in multimodal imaging techniques has presented a unique opportunity to characterize macroscopic and microscopic ophthalmic features associated with health and disease, a field known as oculomics. To date, early detection of dementia and prognostic evaluation of cerebrovascular disease based on oculomics has been realized. Exploiting ophthalmic imaging in this way provides insights beyond traditional ocular observations.

For example, the NeurEYE research program, led by the University of Edinburgh, is using AI to analyze millions of anonymized eye scans to identify biomarkers for Alzheimer’s disease and other neurodegenerative conditions. This research can potentially revolutionize early detection and intervention for these devastating diseases.

Another effort spearheaded by researchers from Penn Medicine, Penn Engineering is exploring the use of AI to analyze retinal images for biomarkers indicative of cardiovascular risk. AI systems are being trained on fundus photography to detect crucial indicators, such as elevated HbA1c levels, a hallmark of high blood sugar, and a significant risk factor for both diabetes and cardiovascular diseases.

Source

AI analysis of retinal characteristics, such as retinal thinning, vascularity reduction, corneal nerve fiber damage, and eye movement, has shown promise in predicting Neurodegenerative diseases. Specifically, decreases in retinal vascular fractal dimension and vascular density have been identified as potential biomarkers for early cognitive impairment, while reductions in the retinal arteriole-to-venular ratio correlate with later stages.

Moving from AI, we now turn to another significant trend identified in our survey:

Optogenetics

Optogenetics represents a significant leap forward in ophthalmic therapeutics, offering a potential solution for vision restoration in patients with advanced retinal degenerative diseases, where traditional gene therapy often falls short. While gene replacement therapies are constrained by the need for viable target cells and the complexity of multi-gene disorders like retinitis pigmentosa (RP), optogenetics offers a broader approach.

This technique aims to circumvent the loss of photoreceptors by introducing light-sensitive proteins, known as opsins, into the surviving inner retinal cells and optic nerve, restoring visual function through light modulation. This method is particularly advantageous as it is agnostic to the specific genetic cause of retinal degeneration.

By delivering opsin genes to retinal neurons, the technology enables the precise manipulation of cellular activity, essentially transforming these cells into new light-sensing units. This approach can bypass the damaged photoreceptor layer, transmitting visual signals directly to the brain.

Several companies are pioneering advancements in this field. RhyGaze, for example, has secured substantial funding to accelerate the development of its lead clinical candidate, a novel gene therapy designed for optogenetic vision restoration. Their efforts encompass preclinical testing, including pharmacology and toxicology studies, an observational study to define clinical endpoints, and a first-in-human trial to assess safety and efficacy. The success of RhyGaze’s research could pave the way for widespread clinical applications, significantly impacting the treatment of blindness globally.

Source

Nanoscope Therapeutics is also making significant strides with its MCO-010 therapy. This investigational treatment, administered through a single intravitreal injection, delivers the Multi-Characteristic Opsin (MCO) gene, enabling remaining retinal cells to function as new light-sensing cells. Unlike earlier optogenetic therapies that required bulky external devices, MCO-010 eliminates the need for high-tech goggles, simplifying the treatment process and enhancing patient convenience. The ability to restore light sensitivity without external devices represents a major advancement, potentially broadening the applicability of optogenetics to a wider patient population.

Source

Another critical area of innovation highlighted in our survey is the advancement of treatments for AMD and GA.

New AMD/GA Treatment

Age-related macular degeneration (AMD) and geographic atrophy (GA) represent a significant challenge in ophthalmology, demanding innovative therapeutic strategies beyond the established anti-VEGF paradigm.

Source

Gene Correction

Gene editing is emerging as a powerful tool in the fight against AMD and GA, potentially correcting the underlying genetic errors that contribute to these diseases. Essentially, it allows us to make precise changes to a patient’s DNA.

Traditional gene editing techniques often rely on creating ‘double-strand breaks’ (DSBs) in the DNA at specific target sites, which are like precise cuts in the DNA strand. These cuts are made using specialized enzymes, like CRISPR-Cas9, which act as molecular scissors. While effective, these methods can sometimes introduce unwanted changes at the cut site, such as small insertions or deletions.

After a DSB is made, the cell’s natural repair mechanisms kick in. There are two main pathways:

• Non-Homologous End Joining (NHEJ): This is the cell’s quick-fix method. It essentially glues the broken ends back together. However, this process can sometimes introduce errors, leading to small insertions or deletions that can disrupt the gene’s function.
• Homology-Directed Repair (HDR): This is a more precise repair method. It uses a ‘donor’ DNA template to guide the repair process, ensuring accuracy. However, HDR is more complex and less efficient, especially in non-dividing cells.

To overcome these limitations of traditional gene editing, researchers have developed more precise techniques:

• Base Editing: This technique allows scientists to change a single ‘letter’ in the DNA code without creating DSBs.
• Prime Editing: This advanced technique builds upon CRISPR-Cas9, allowing for a wider range of precise DNA changes. It can correct most disease-causing mutations with enhanced safety and accuracy.
• CASTs (CRISPR-associated transposases): This method enables larger DNA modifications without creating DSBs, offering a safer approach to genetic correction.

Why does this matter for AMD and GA? These advancements in gene editing are crucial for addressing the genetic roots of these pathologies. We can potentially develop more effective and targeted therapies by precisely correcting the faulty genes that contribute to these diseases. The technologies are still being researched, but they hold great promise for the future of ophthalmology.

Cell Reprogramming

Cell reprogramming offers a novel approach to regenerative medicine, with the potential to replace damaged retinal cells. This technique involves changing a cell’s fate, either in vitro or in vivo. In vitro reprogramming involves extracting cells, reprogramming them in a laboratory, and then transplanting them back into the patient. In vivo reprogramming, which directly reprograms cells within the body, holds particular promise for retinal diseases. This approach has succeeded in preclinical studies, demonstrating the potential to restore vision in conditions like congenital blindness.

Vectors and Delivery Methods

The success of gene therapy relies on efficiently delivering therapeutic genes to target retinal cells. Vectors are essentially delivery vehicles, designed to carry therapeutic genes into cells. These vectors can be broadly classified into two categories: viral and non-viral. Vectors, both viral and non-viral, are crucial for this process.

Viral vectors are modified viruses that have been engineered to remove their harmful components and replace them with therapeutic genes. They are highly efficient at delivering genes into cells, as they have evolved to do just that. Adeno-associated viruses (AAVs) are the most commonly used viral vectors in ocular gene therapy due to their safety profile and cell-specificity. The diversity of AAV serotypes allows for tailored gene delivery to specific retinal cell types.

Non-viral vectors, on the other hand, are synthetic systems that don’t rely on viruses. They can be made from lipids, polymers, or even DNA itself. While they may be less efficient than viral vectors, they offer safety and ease of production advantages.

Advances in vector design, whether viral or non-viral, are focused on enhancing gene expression, cell-specificity, and carrying capacity.

Now, let’s examine the ongoing evolution of anti-VEGF treatments, a cornerstone of modern retinal care.

New Anti-VEGF drugs

The landscape of ophthalmology has undergone a dramatic transformation since the early 1970s when Judah Folkman first proposed the concept of tumor angiogenesis. His idea sparked research that ultimately led to the identification of vascular endothelial growth factor (VEGF) in 1989 and the development of anti-VEGF therapies, revolutionizing the treatment of neovascular eye diseases, dramatically improving outcomes for patients with wet AMD, diabetic retinopathy, and retinal vein occlusions.

Population-based studies have shown a substantial reduction (up to 47%) in blindness due to wet AMD since the introduction of anti-VEGF therapies. However, significant gaps remain despite this progress, especially regarding treatment durability. Anti-VEGF drugs require frequent intravitreal injections, which can be difficult for patients due to time commitments, financial costs, and potential discomfort. Although newer agents have extended treatment intervals, patient adherence and undertreatment challenges persist in real-world settings. Innovative approaches are being investigated to address these unmet needs to increase drug durability and reduce the treatment burden.

Tyrosine Kinase Inhibitors

One approach to increasing treatment durability is using tyrosine kinase inhibitors (TKIs). TKIs are small-molecule drugs that act as pan-VEGF blockers by binding directly to VEGF receptor sites inside cells, offering a different action mechanism than traditional anti-VEGF drugs that target circulating VEGF proteins.

Currently, TKIs are being investigated as maintenance therapy, primarily in conjunction with sustained-release delivery systems. Two promising TKIs for retinal diseases are axitinib and vorolanib. In a bioresorbable hydrogel implant, Axitinib is being studied for neovascular AMD and diabetic retinopathy. Vorolanib, in a sustained-release delivery system, is also being investigated for neovascular AMD. These TKIs offer the potential for less frequent dosing, reducing the treatment burden for patients.

Port Delivery System

The Port Delivery System (PDS) is a surgically implanted, refillable device that provides continuous ranibizumab delivery for up to 6 months. While it’s FDA-approved for neovascular AMD, it’s also being investigated for other retinal diseases, such as diabetic macular edema and diabetic retinopathy.

Source

Although the PDS faced a voluntary recall due to issues with septum dislodgment, it has returned to the market with modifications. The PDS offers the potential for significantly reduced treatment frequency for a subset of patients. However, challenges remain, including the need for meticulous surgical implantation and the risk of endophthalmitis.

Nanotechnology

Nanotechnology offers promising solutions to overcome limitations of current ocular drug delivery. The unique structure of the eye, with its various barriers, poses challenges for drug delivery. Topical administration often fails to achieve therapeutic concentrations, while frequent intravitreal injections carry risks. Nanotechnology can improve drug solubility, permeation, and bioavailability through nanoparticles, potentially extending drug residence time and reducing the need for frequent injections. Several nanoparticle systems, lipid and polymeric, are being studied for ocular drug delivery, offering hope for more effective and less invasive treatments.

Summing up

The advancements discussed in this article, encompassing AI, optogenetics, novel AMD/GA therapies, and refined anti-VEGF treatments, collectively signal a transformative era for ophthalmology. As highlighted by the survey results, AI probably encompasses most of the changes by redefining diagnostic and clinical workflows through its capacity for image analysis, biomarker identification, and personalized patient management.

Optogenetics offers a distinct pathway to vision restoration, bypassing limitations of traditional gene therapy. The progress in AMD/GA treatments, particularly gene editing and cell reprogramming, presents opportunities for targeted interventions. Finally, the evolution of anti-VEGF therapies, with innovations in drug delivery and sustained-release mechanisms, addresses persistent challenges in managing neovascular diseases.

These developments, driven by technological innovation and clinical research, promise to enhance patient outcomes and reshape the future of ophthalmic care.

Disclaimer: USA FDA 510(k) Class II; Altris Image Management System (Altris IMS); AI/ML models and components intended to use for research purposes only, not for clinical diagnosis purposes.